Spots Global Cancer Trial Database for Pulmonary sarcomatoid_MEDI4736+Treme
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pulmonary sarcomatoid_MEDI4736+Treme
Official Title: Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Study ID: NCT03022500
Interventions
Study Description
Brief Summary: To understand efficacy of Durvalumab(MEDI4736)+ Tremelimumab in Metastatic/relapsed pulmonary sarcomatoid carcinoma
Detailed Description: This is a phase II multi-center, open-label study to evaluate efficacy and safety of durvalumab + tremelimumab combination treatment in patients with pulmonary sarcomatoid carcinoma
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Internal Medicine, Seoul National University Hospital, Seoul, , Korea, Republic of
Contact Details
Name: Bhumsuk Kim, Ph.D.
Affiliation: Seoul National University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
